Semaglutide Generic Medications Surge in India Following Patent Expiration

Semaglutide Generics Disrupt Market in India, Outpacing Novo Nordisk's Brands

In a swift and decisive shift, generic versions of anti-diabetes and weight-loss medication Semaglutide have surpassed Novo Nordisk and its partner brands in volumes in India, mere weeks after the diabetes and obesity drug lost patent protection. The rapid ascent of Semaglutide generics underscores the profound impact of lower prices and deep distribution on a blockbuster market, effectively redrawing the landscape almost overnight.

Following the patent expiry in March 2026, a wave of domestic drugmakers, including Torrent Pharmaceuticals, Zydus Lifesciences, Lupin, and Dr. Reddy’s Laboratories, launched lower-cost versions of semaglutide. This development pushed the therapy beyond its earlier urban, premium niche, significantly widening adoption across diabetes care, obesity treatment, and preventive wellness.

Industry data reveals the extent of this shift. By April, the impact was already visible in the numbers, with India's anti-diabetic segment growing 16.2 percent, outpacing most other therapies. Semaglutide generics emerged as a key driver, with their cumulative scale outpacing Novo's own brands.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

While Novo's own brands continue to post solid sales, the real disruption lies in the cumulative scale of generics. Individually, these products may trail Novo's top brands, but together they are already outpacing the innovator in prescription volumes.

The underlying driver of this shift is affordability. For years, semaglutide remained out of reach for most patients due to its high price, limiting its use largely to metros. However, with the entry of generics, prices have been slashed by up to 90 percent, with some vial versions retailing for as low as Rs.1,290 per month. In response, Novo Nordisk has reduced its own monthly prices by up to 48 percent to approximately Rs.5,660, narrowing its premium to defend market share against the new competitors.

This shift has effectively expanded the market rather than just redistributed it, turning semaglutide into a mass-market chronic therapy almost immediately after patent expiry. The nature of competition, characterized by multiple companies launching products simultaneously, has intensified competition, accelerated doctor outreach, and ensured deeper penetration into India's vast non-metro markets.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Industry experts believe that the market has the potential to reach Rs.2,000-2,500 crore, with Nirav Mehta, CEO and Managing Director of Corona Remedies, stating that it would take another 3-4 months to see how big this market would be.